CAMILA Drug Patent Profile
✉ Email this page to a colleague
When do Camila patents expire, and when can generic versions of Camila launch?
Camila is a drug marketed by Dr Reddys Labs Sa and is included in one NDA.
The generic ingredient in CAMILA is norethindrone. There are twenty-six drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the norethindrone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Camila
A generic version of CAMILA was approved as norethindrone by GLENMARK GENERICS on July 22nd, 2010.
Summary for CAMILA
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 76 |
Clinical Trials: | 1 |
Patent Applications: | 3,781 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for CAMILA |
DailyMed Link: | CAMILA at DailyMed |
Recent Clinical Trials for CAMILA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of California, San Diego | Phase 4 |
Pharmacology for CAMILA
Drug Class | Progestin |
US Patents and Regulatory Information for CAMILA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dr Reddys Labs Sa | CAMILA | norethindrone | TABLET;ORAL-28 | 076177-001 | Oct 21, 2002 | AB1 | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |